- Trusted Product Information
Our Story
Built to Close the Gap Between Discovery and Application
Lilac Biosciences started with one question that wouldn’t go away: why is it still so hard to move RNA insight out of the lab and into a real study?
Our Trusted Collaborators
From Brown University to the Bench
Understand each development phase that transforms scientific discovery into safe, effective, and approved medical treatments.
DISCOVERY & PRECLINICAL
REGULATORY OVERVIEW
CLINICAL TRIALS ( PHASE 1 - 3 )
Driven by Science, Committed to Health
Pioneering medical innovation with trusted expertise, global collaboration, and unwavering dedication to patient care.
Cardiovex-101
Target Indication: Hypertension
Development Stage: Hypertension
Cardiovex-101 is an innovative small-molecule therapeutic designed to manage moderate to severe hypertension. This candidate works by selectively inhibiting angiotensin receptors to reduce vascular resistance and improve cardiac output without significantly impacting renal function.
- Currently in Phase II clinical trials, Cardiovex-101 has demonstrated statistically significant reductions in both systolic and diastolic blood pressure across a diverse patient population
- First-in-class mechanism targeting dual pathways of vascular regulation Oral, once-daily formulation for improved patient compliance
- Pending Phase II results, the program is expected to advance to Phase III trials by early next year, focusing on long-term outcomes and broader population efficacy.
From Discovery to Cure, Clearly Tracked
Stay informed with every research phase and milestone on our development journey
01
Discovery Initiation — Q2 2023
Initial compound screening and biomarker identification began for autoimmune disease therapy targeting T-cell modulation.
02
Preclinical Validation — Q4 2023
Initial compound screening and biomarker identification began for autoimmune disease therapy targeting T-cell modulation.
03
Phase I Enrollment — Q1 2024
Initial compound screening and biomarker identification began for autoimmune disease therapy targeting T-cell modulation.
04
Phase III Protocol Finalization — Q3 2025
Completed NDA (New Drug Application) submission to FDA and EMA for respiratory drug RespiraX-22 after successful Phase III trials.Initiated manufacturing scale-up and global distribution strategy for diabetes treatment Glucorin-5, targeting 18 countries by launch.
05
Market Launch Preparation — Q2 2026
Completed NDA (New Drug Application) submission to FDA and EMA for respiratory drug RespiraX-22 after successful Phase III trials.Initiated manufacturing scale-up and global distribution strategy for diabetes treatment Glucorin-5, targeting 18 countries by launch.
